본문으로 건너뛰기
← 뒤로

Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma: A Rare and Aggressive Case Report with Clinical and Pathological Insights.

증례보고 1/5 보강
Journal of clinical medicine 📖 저널 OA 100% 2021: 34/34 OA 2022: 61/61 OA 2023: 78/78 OA 2024: 135/135 OA 2025: 265/265 OA 2026: 192/192 OA 2021~2026 2025 Vol.14(21)
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
methotrexate with partial response but experienced disease relapse during second-line etoposide therapy
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
However, therapeutic options remain limited, and outcomes are poor despite systemic chemotherapy. Further research into targeted and personalized therapies is urgently needed to improve survival in this devastating disease.

Jaramillo J, Méndez-Flores K, Lascano N, Palacios-Álvarez S, Arias-Intriago M, Izquierdo-Condoy JS

📝 환자 설명용 한 줄

Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma (PCAETL) is a rare and highly aggressive subtype of cutaneous T-cell lymphoma (CTCL), accounting for less than 1% of CTCL cas

이 논문을 인용하기

↓ .bib ↓ .ris
APA Jaramillo J, Méndez-Flores K, et al. (2025). Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma: A Rare and Aggressive Case Report with Clinical and Pathological Insights.. Journal of clinical medicine, 14(21). https://doi.org/10.3390/jcm14217842
MLA Jaramillo J, et al.. "Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma: A Rare and Aggressive Case Report with Clinical and Pathological Insights.." Journal of clinical medicine, vol. 14, no. 21, 2025.
PMID 41227238 ↗
DOI 10.3390/jcm14217842

Abstract

Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma (PCAETL) is a rare and highly aggressive subtype of cutaneous T-cell lymphoma (CTCL), accounting for less than 1% of CTCL cases. It is defined by CD8+ cytotoxic T-cell proliferation with marked epidermotropism, necrosis, and a high proliferative index. Clinically, it presents as ulcerated or necrotic lesions with rapid progression and poor response to conventional therapies. To describe a fatal case of PCAETL in a young adult female, emphasizing the diagnostic challenges, clinical progression, histopathological features, and treatment limitations. A 41-year-old Venezuelan woman presented with a 10-month history of disseminated papules and nodules initially misdiagnosed as Hansen's disease. After her arrival in Ecuador, she was re-evaluated and found to have generalized dermatosis with ulcerated nodules and tumors. Histopathological examination revealed atypical epidermotropic CD8+ T-cell infiltration with extensive necrosis. Immunohistochemistry demonstrated strong positivity for CD3, CD5, and CD8, and a Ki-67 index of 80%, confirming the diagnosis of PCAETL. The patient received methotrexate with partial response but experienced disease relapse during second-line etoposide therapy. She developed febrile neutropenia and died five months after diagnosis. This case highlights the rarity, diagnostic complexity, and aggressive nature of PCAETL. Early recognition and clinico-pathological correlation are essential for timely diagnosis. However, therapeutic options remain limited, and outcomes are poor despite systemic chemotherapy. Further research into targeted and personalized therapies is urgently needed to improve survival in this devastating disease.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기